Menu Search
Equities

Xvivo Perfusion AB

3XV:DEU

Xvivo Perfusion AB

Actions
  • Price (EUR)39.05
  • Today's Change-1.10 / -2.74%
  • Shares traded0.00
  • 1 Year change+89.56%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Xvivo Perfusion AB grew revenues 43.88% from 415.29m to 597.54m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 398.29% net income growth from 18.43m to 91.82m.
Gross margin74.41%
Net profit margin27.21%
Operating margin7.56%
Return on assets9.05%
Return on equity10.18%
Return on investment9.68%
More ▼

Cash flow in SEKView more

In 2023, Xvivo Perfusion AB increased its cash reserves by 121.50%, or 299.54m. Cash Flow from Financing totalled 418.55m or 70.04% of revenues. In addition the company generated 46.29m in cash from operations while cash used for investing totalled 161.62m.
Cash flow per share8.85
Price/Cash flow per share51.64
Book value per share66.13
Tangible book value per share25.32
More ▼

Balance sheet in SEKView more

Xvivo Perfusion AB has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 546.09m.
Current ratio5.49
Quick ratio4.23
Total debt/total equity0.0118
Total debt/total capital0.0117
More ▼

Growth rates in SEK

SmartText is unavailable
EPS growth(5 years)44.77
EPS (TTM) vs
TTM 1 year ago		715.97
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.